Self-replicating RNA subunit vaccines for avian infectious bronchitis virus
Innovative srRNA vaccine platform offers rapid, scalable protection against diverse IBV serotypes in poultry. By encoding conserved antigens, it provides broad immunity using minimal doses, overcoming the limitations of traditional vaccines.
Overview
The proposed self-replicating RNA (srRNA) vaccine platform aims to revolutionize the prevention of Avian Infectious Bronchitis Virus (IBV) in poultry. By encoding conserved subunit antigens such as S2 and nucleocapsid proteins, this technology promises broad immune coverage across diverse serotypes with significantly lower doses compared to traditional mRNA vaccines. Unlike conventional egg-based vaccines, this srRNA platform is synthetically produced via in vitro transcription, allowing for rapid scale-up and adaptability to emerging viral variants. Its compatibility with existing poultry vaccine delivery methods, such as spray or in ovo, ensures it meets industry needs for mass administration.
Technical specifications
- Self-replicating RNA technology: Amplifies antigen expression within avian cells, generating robust humoral and cellular immunity.
- Conserved antigen targeting: Focuses on stable protein regions (S2, nucleocapsid) to induce cross-protective immune responses.
- Scalable production: Synthetic production via in vitro transcription enables rapid industrial scale-up.
- Flexible delivery methods: Compatible with commercial poultry vaccine techniques, including spray and in ovo delivery.
- Rapid adaptability: Allows for quick updates and modifications in response to new IBV variants.
Technology readiness level
The srRNA vaccine platform is currently at Technology Readiness Level 3, with ongoing development focused on optimizing vector backbones, formulations, and conducting in vivo testing to assess safety and immune response in poultry.
About Duke University
Duke University is a mid-sized, comprehensive private research university in Durham, North Carolina, anchored by a globally recognized academic medical center. Co-located campus and clinical facilities enable rapid bench-to-bedside translation, and shared core laboratories are accessible to external partners. Proximity to Research Triangle Park links Duke to a dense network of R&D-intensive companies, supported by centralized corporate engagement for sponsored research and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD. A dedicated technology transfer office supports IP strategy, licensing, startups, and industry collaboration.
delivered to your inbox.